Steven Cohen’s Lexeo Therapeutics LXEO Stock Holding History

Steven Cohen’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,680,449	Closed	-$9.65M	–	4352
2026 Q1	$9.65M	Sell	1,680,449 -214,273	-11%	-$1.52M	0.01%	1283
2025 Q4	$18.8M	Sell	1,894,722 -47,127	-2%	-$430K	0.02%	931
2025 Q3	$12.9M	Buy	1,941,849 +1,293,969	+200%	+$6.26M	0.02%	705
2025 Q2	$2.6M	Sell	647,880 -450,263	-41%	-$1.48M	0.01%	1190
2025 Q1	$3.81M	Buy	1,098,143 +347,908	+46%	+$1.54M	0.01%	1026
2024 Q4	$4.94M	Buy	750,235 +379,828	+103%	+$2.99M	0.01%	949
2024 Q3	$3.35M	Buy	+370,407	New	+$4.42M	0.01%	1001

Other funds holding LXEO

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Steven Cohen's LXEO Position: Q2 2026 in Review

Steven Cohen sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 1,680,449 shares — an estimated $9.65M sold.

Steven Cohen first reported a position in LXEO in Q3 2024 and held it in 7 quarters. The position peaked at $18.8M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

Steven Cohen reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 1,680,449 Lexeo Therapeutics shares in Q2 2026, an estimated $9.65M.
Steven Cohen first reported a position in Lexeo Therapeutics in Q3 2024 and held it in 7 quarters.
Steven Cohen's Lexeo Therapeutics position peaked at $18.8M in Q4 2025.
141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.